- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Future Directions for Type 2 Inflammation Management
Reynold A. Panettieri Jr., MD, examines the application of biologic therapies in the treatment of respiratory conditions.
EP: 1.Navigating the Challenges of Respiratory Diseases
EP: 2.The Impact of Atopic Dermatitis and Prurigo Nodularis
EP: 3.Linking Type 2 Inflammation to Asthma and COPD
EP: 4.Impact of Exacerbations in Type 2 Inflammatory Respiratory Diseases
EP: 5.Type 2 Inflammation: The Link Between AD and PN
EP: 6.Personalizing Treatment Selection
EP: 7.Navigating Treatment Challenges in Chronic Skin Conditions
EP: 8.Role of Biologics in Dermatological Care
EP: 9.Biomarkers as Tools in Management of Type 2 Inflammation
EP: 10.Strategies to Manage Type 2 Inflammation in Respiratory Diseases
EP: 11.Addressing Unmet Needs and Emerging Agents
EP: 12.Future Directions for Type 2 Inflammation Management
EP: 13.Type 2 Inflammatory Diseases and Impact on Quality of Life
EP: 14.Type 2 Inflammation Biomarkers
EP: 15.How Type 2 Inflammation Influences Treatment Choices
EP: 16.Complications of Uncontrolled Disease and Management of Comorbidities
EP: 17.Patient Education and Emerging Therapies
EP: 18.Unmet Needs and Future Research
- Biologics are currently available for asthma management and being studied in COPD patients. Where do you envision the potential place of biologic therapies in the treatment algorithm for patients with type 2 inflammation-driven COPD?
- How does the route of administration impact the treatment selection?
- What emerging therapies for type 2 inflammation related to respiratory diseases are you most excited about? What are clinical trial data showing in terms of exacerbation and hospitalization rates, patient quality of life, and general disease management?
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
